In collaboration with a major pharmaceutical partner, King’s College London is launching a substantial programme of basic and translational research into understanding the early molecular and immunological events that lead to the establishment Clonal Haemopoiesis and early stages of Myelodysplastic Syndrome (MDS). Comparison of these early events with subsequent molecular phenotypes of MDS and Acute Myeloid Leukaemia (AML) should help to identify targets for therapeutic intervention. It is anticipated we will recruit over 6,000 patients undergoing hip replacements as a healthy ageing cohort for the study to follow for at least 5 years; continuing to observe changes to health and haematology profiles. The programme aims to build one of the largest Biobanks to interrogate associations between immune and genetic changes in the blood and diseases that increase in prevalence with age and to enable future translational research endeavours. There is therefore an urgent need to develop reliable tools for patient stratification in order to ensure that only those likely to benefit are given a specific treatment.
The post holder will contribute expertise in applying technologies of all types associated with the stratification of patients for immune-oncology treatments. As part of this job, the post holder will contribute in designing a major database, developing pipelines to analyse and integrate multiple biological research and clinical data streams, and generating insights that drive the elucidation of key disease mechanisms. The project involves (and not limited to) multi-omic (Genomics, single-cell RNAseq, ChIP-seq, Methyl-seq, metabolomics, and microbiomics) and mass-cytometry (CyTOF) data analysis of blood samples.